Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics’ existing sacral neuromodulation (SNM) offering.
Physicians determine a patient’s eligibility for long-term SNM therapy by performing an external trial or peripheral nerve evaluation (PNE). The temporary lead that is placed during a PNE is often done in the office setting without real-time imaging (i.e., fluoroscopy). Due to anatomic variability between patients, locating the appropriate sacral foramen (closest to the desired root of the sacral nerve) can be challenging without fluoroscopy and can hinder physicians’ confidence in the procedure. The acquired technology addresses this challenge with an elegant solution comprising a software application and a hardware tool that makes PNE lead placement easier, faster, and more accurate.
The technology has the potential to reduce procedure time and facilitate a more accurate placement which, in turn, can increase physicians’ confidence in the SNM procedure and drive increased therapy adoption, utilization and permanent implant conversion rates. With a standard x-ray image of a patient’s pelvis, a physician can leverage the software to determine the optimal location for needle entry and lead placement based on the patient’s specific anatomy. The technology can readily be implemented into existing clinical workflows as it takes only minutes to use and requires minimal training.
Axonics has acquired the assets of Radian, LLC from Intermed Labs for undisclosed terms. Axonics expects the product to receive FDA clearance and be available on a commercial basis in mid-2024.
“Since Axonics’ founding, our SNM development efforts have focused on enhancing the physician and patient experience,” said Raymond W. Cohen, chief executive officer of Axonics. “We expect the Radian technology will improve patient comfort, increase physician confidence and SNM access, simplify the learning curve for physicians new to SNM, and increase PNE trial success rates, which should ultimately result in more adults being treated with our life-changing SNM therapy. We are confident that empowering physicians with innovative technology and tools has the potential to drive significant SNM market expansion in the years ahead.”
